Cannabichromene: An Anti-inflammatory Cannabinoid

Cannabichromene (CBC), also known as cannabichrome, is a phytocannabinoid found in the cannabis plant, among hundreds of others. Known for its anti-inflammatory properties in vitro, CBC could contribute to the analgesic effects of cannabis.

Origin and Structure

CBC has structural similarities to other cannabinoids like THC, CBD, and CBN. It is produced in the cannabis plant primarily as cannabichromenic acid (CBCA), which converts to CBC over time or when heated.

Pharmacological Properties

CBC interacts with TRPV1 and TRPA1 receptors, potentially influencing the psychoactivity of THC, although this has not been demonstrated in vivo. Studies have also shown its antitumor effects on mouse breast cancer xenografts, as well as its anticonvulsant activity in mouse models..

Activity on Cannabinoid Receptors

In vitro, CBC binds weakly to CB1 and CB2 receptors, acting as an agonist for cAMP stimulation and an antagonist for beta-arrestin. Additionally, CBC acts as an agonist of TRPA1 and, to a lesser extent, TRPV3 and TRPV4.

"In vitro" refers to studies carried out outside the normal biological context, using microorganisms, cells or biological molecules. These experiments, often called "test tube experiments", are conducted in laboratory equipment such as test tubes or Petri dishes. They allow detailed or convenient analysis of isolated biological components, but results may not always fully predict effects on an entire organism. In contrast, "in vivo" studies are conducted on living organisms, including humans and animals, and are often clinical trials.

Outlook

Although CBC is less studied than other cannabinoids like THC and CBD, its promising pharmacological properties are attracting growing interest in medical research. Further studies are needed to better understand its therapeutic potential and clinical applications.

" Do not hesitate to share your experiences and opinions on cannabis molecules in the comments below, while discovering our blog and sharing its content on your social networks. Your support is our driving force!"